Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2018.0272

EDITORIAL

Developing new targeted drugs for resectable gastric cancer.

Dimitrios Schizas, MD, PhD.

Affiliation:Dimitrios Schizas, (DS), 1st Department of Surgery, Laikon General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece.

Tel:+302651005571

E-mail: schizasad@gmail.com

Abstract
Standardized D2 gastrectomy with adjuvant chemotherapy for resected gastric cancer has improved survival, but recurrence and mortality rates remain high. The recent advent of genome analysis with next-generation sequencing (NGS) opens new therapeutic avenues for overcoming the clinical unmet needs.

(Citation: Gastric & Breast Cancer 2018; 13(1): 1-7)

Back

 

You can have an online full-text access and a PDF of this article:
  • Either purchase this paper for €35 EUR. Please, click here
Please specify DOI of article
  • Or through one year subscription PayPal

Online ISSN : 1109 - 7647
   Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 31 March 2018